CDEK
← All organizations

TG Therapeutics, Inc.

For profitContributed to NMEWebsite ↗

Also known as: TG Therapeutics | TG Therapeutics, Inc. | TG THERAPEUTICS, INC | TG THERAPS

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Aug 1, 2012

First marketed drug

Feb 5, 2021

First NDA

Feb 5, 2021

Last known activity

Jan 1, 2026

Timeline

1990s

  1. Jan 1, 1993

    TG Therapeutics, Inc.— Founded

2010s

  1. Dec 29, 2011

    Manhattan Pharmaceuticals— Acquired

2020s

  1. Feb 5, 2021

    umbralisib— Marketing Organization

  2. Feb 5, 2021

    umbralisib— NDA Organization

  3. Feb 5, 2021

    umbralisib— NDA Secondary Org

Drugs by trial phase (27 distinct, 47 trials)

Phase 4 (1 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (2)

Subsidiaries (1 direct, 2 total across the full acquisition tree)

Recent trials (45)

Details

Founded
New York, NY, US Jan 1, 1993
First NDA
Feb 5, 2021
Last known activity
Jan 1, 2026

Designations held

  • Orphan drug
  • Priority review
  • Breakthrough therapy
  • Accelerated approval